Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer
详细信息 查看全文
- 作者：Kyueng-Whan Min ; Dong-Hoon Kim ; Sung-Im Do ; Seoung Wan Chae…
- 关键词：GATA3 protein ; Fascin protein ; Prognosis ; Breast cancer
- 刊名：Virchows Archiv
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：468
- 期：4
- 页码：409-416
- 全文大小：549 KB
- 参考文献：1.Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Investig 26(1):1–10. doi:10.1080/07357900701784238 CrossRef
2.Naderi A, Teschendorff AE, Barbosa-Morais NL, et al. (2007) A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26(10):1507–1516. doi:10.1038/sj.onc.1209920 CrossRef PubMed
3.Masuda S (2012) Breast cancer pathology: the impact of molecular taxonomy on morphological taxonomy. Pathol Int 62(5):295–302. doi:10.1111/j.1440-1827.2012.02790.x CrossRef PubMed
4.Harris L, Fritsche H, Mennel R, et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312. doi:10.1200/JCO.2007.14.2364 CrossRef PubMed
5.Ahn SG, Jeong J, Hong S, Jung WH (2015) Current issues and clinical evidence in tumor-infiltrating lymphocytes in breast cancer. J Pathol Transl Med 49(5):355–363. doi:10.4132/jptm.2015.07.29 CrossRef PubMed PubMedCentral
6.Ali HR, Dawson SJ, Blows FM, et al. (2012) A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol 226(1):97–107. doi:10.1002/path.2976 CrossRef PubMed
7.Lee HK, Lee HS, Yang HK, et al. (2003) Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Color Dis 18(6):518–525. doi:10.1007/s00384-003-0491-2 CrossRef
8.Cameron RI, Maxwell P, Jenkins D, McCluggage WG (2002) Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 41(4):313–321CrossRef PubMed
9.Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z (2006) GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127(5):1041–1055. doi:10.1016/j.cell.2006.09.048 CrossRef PubMed PubMedCentral
10.Ting CN, Olson MC, Barton KP, Leiden JM (1996) Transcription factor GATA-3 is required for development of the T-cell lineage. Nature 384(6608):474–478. doi:10.1038/384474a0 CrossRef PubMed
11.Pai SY, Truitt ML, Ting CN, Leiden JM, Glimcher LH, Ho IC (2003) Critical roles for transcription factor GATA-3 in thymocyte development. Immunity 19(6):863–875CrossRef PubMed
12.Tong Q, Dalgin G, Xu H, Ting CN, Leiden JM, Hotamisligil GS (2000) Function of GATA transcription factors in preadipocyte-adipocyte transition. Science 290(5489):134–138CrossRef PubMed
13.Grote D, Souabni A, Busslinger M, Bouchard M (2006) Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development 133(1):53–61. doi:10.1242/dev.02184 CrossRef PubMed
14.Tsarovina K, Pattyn A, Stubbusch J, Muller F, van der Wees J, Schneider C, Brunet JF, Rohrer H (2004) Essential role of gata transcription factors in sympathetic neuron development. Development 131(19):4775–4786. doi:10.1242/dev.01370 CrossRef PubMed
15.Kaufman CK, Zhou P, Pasolli HA, et al. (2003) GATA-3: an unexpected regulator of cell lineage determination in skin. Genes Dev 17(17):2108–2122. doi:10.1101/gad.1115203 CrossRef PubMed PubMedCentral
16.Voduc D, Cheang M, Nielsen T (2008) GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomark Prev 17(2):365–373. doi:10.1158/1055-9965.EPI-06-1090 CrossRef
17.Tominaga N, Naoi Y, Shimazu K, et al. (2012) Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy. Ann Oncol 12:3051–3057. doi:10.1093/annonc/mds120 CrossRef
18.Dydensborg AB, Rose AA, Wilson BJ, et al. (2009) GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene 28(29):2634–2642. doi:10.1038/onc.2009.126 CrossRef PubMed
19.Gonzalez RS, Wang J, Kraus T, Sullivan H, Adams AL, Cohen C (2013) GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. Hum Pathol 44(6):1065–1070. doi:10.1016/j.humpath.2012.09.010 CrossRef PubMed
20.Sun J, He H, Pillai S, et al. (2013) GATA3 transcription factor abrogates Smad4 transcription factor-mediated fascin overexpression, invadopodium formation, and breast cancer cell invasion. J Biol Chem 288(52):36971–36982. doi:10.1074/jbc.M113.506535 CrossRef PubMed PubMedCentral
21.Hsu KF, Lin CK, Yu CP, et al. (2009) Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Dis Esophagus 22(5):402–408. doi:10.1111/j.1442-2050.2008.00921.x CrossRef PubMed
22.Al-Alwan M, Olabi S, Ghebeh H, et al. (2011) Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One 6(11):e27339. doi:10.1371/journal.pone.0027339 CrossRef PubMed PubMedCentral
23.Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC (2006) Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer 6:241. doi:10.1186/1471-2407-6-241 CrossRef PubMed PubMedCentral
24.Pelosi G, Pastorino U, Pasini F, et al. (2003) Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 88(4):537–547. doi:10.1038/sj.bjc.6600731 CrossRef PubMed PubMedCentral
25.Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M (2004) The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 67(3–4):262–270. doi:10.1159/000081327 CrossRef PubMed
26.Tong GX, Yee H, Chiriboga L, Hernandez O, Waisman J (2005) Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol 36(7):741–746. doi:10.1016/j.humpath.2005.05.005 CrossRef PubMed
27.Grothey A, Hashizume R, Sahin AA, McCrea PD (2000) Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 83(7):870–873. doi:10.1054/bjoc.2000.1395 CrossRef PubMed PubMedCentral
28.Yoder BJ, Tso E, Skacel M, et al. (2005) The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 11(1):186–192PubMed
29.Esnakula AK, Ricks-Santi L, Kwagyan J, et al. (2014) Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women. J Clin Pathol 67(2):153–160. doi:10.1136/jclinpath-2013-201698 CrossRef PubMed
30.Robbins P, Pinder S, de Klerk N, et al. (1995) Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26(8):873–879CrossRef PubMed
31.Hammond ME, Hayes DF, Dowsett M, et al. (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7):e48–e72. doi:10.1043/1543-2165-134.7.e48 PubMed
32.Rakha EA, Starczynski J, Lee AH, Ellis IO (2014) The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. Histopathology 64(5):609–615. doi:10.1111/his.12357 CrossRef PubMed
33.Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA ) in breast cancer tissue. Pathologe 8(3):138–140PubMed
34.Cheang MC, Chia SK, Voduc D, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750. doi:10.1093/jnci/djp082 CrossRef PubMed PubMedCentral
35.Gu MJ, Kim JY, Park JB (2014) Fascin expression predicts lymph node metastasis and worse survival in small intestinal carcinoma. Pathology 46(1):21–24. doi:10.1097/PAT.0000000000000024 CrossRef PubMed
36.Vignjevic D, Schoumacher M, Gavert N, et al. (2007) Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res 67(14):6844–6853. doi:10.1158/0008-5472.CAN-07-0929 CrossRef PubMed
37.Yan W, Cao QJ, Arenas RB, Bentley B, Shao R (2010) GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem 285(18):14042–14051. doi:10.1074/jbc.M110.105262 CrossRef PubMed PubMedCentral
38.Chen L, Yang S, Jakoncic J, Zhang JJ, Huang XY (2010) Migrastatin analogues target fascin to block tumour metastasis. Nature 464(7291):1062–1066. doi:10.1038/nature08978 CrossRef PubMed PubMedCentral
39.Sun J, He H, Xiong Y, et al. (2011) Fascin protein is critical for transforming growth factor beta protein-induced invasion and filopodia formation in spindle-shaped tumor cells. J Biol Chem 286(45):38865–38875. doi:10.1074/jbc.M111.270413 CrossRef PubMed PubMedCentral - 作者单位：Kyueng-Whan Min (1)
Dong-Hoon Kim (2)
Sung-Im Do (2)
Seoung Wan Chae (2)
Kyungeun Kim (2)
Jin Hee Sohn (2)
Jung-Soo Pyo (2)
Hyun Joo Lee (2)
Dong Hyun Kim (2)
Sukjoong Oh (3)
Seon Hyeong Choi (4)
Yong Lai Park (5)
Chan Heun Park (5)
Eun-Kyung Kim (6)
Mi Jung Kwon (1)
Jinwon Seo (1)
Kyoung Min Moon (7)
1. Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Gyeonggi-do, Republic of Korea
2. Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-Gu, Seoul, 110-746, Republic of Korea
3. Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
4. Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
5. Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
6. Department of Pathology, Eulji General Hospital, Eulji University School of Medicine, Seoul, Republic of Korea
7. Department of Internal Medicine, Eulji University Hospital, Eulji University School of Medicine, Daejeon, Republic of Korea - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Pathology - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-2307
文摘
GATA3 and fascin proteins are known prognostic markers in several cancers. GATA3 is a key regulator of mammary gland morphogenesis and luminal cell differentiation, whereas fascin is a pro-metastatic actin-bundling protein. In this study, we analyzed and compared the predictive abilities of GATA3 and fascin for clinical outcomes of patients with breast cancer. The combined expression pattern based on GATA3−/+ and fascin−/+ was evaluated by immunostaining using a tissue microarray, and relationships between protein expression and several clinicopathological parameters were analyzed. GATA3 expression was associated with good prognostic parameters, but fascin was correlated with poor prognostic parameters. On comparing GATA3 and fascin, we found an inverse relationship between fascin and GATA3 expressions. On analysis of combined markers, GATA3+/fascin− was correlated with improved clinical outcomes compared to GATA3−/fascin+. Univariate and multivariate analyses revealed significant differences in relapse-free and overall survival between GATA3+/fascin− and GATA3−/fascin+. Combined marker analysis of GATA3/fascin showed an inverse association and improved prognostic information for patients with breast cancer.